Studies cadonilimab in people with cervical cancer that has returned or spread
Follows adults with cervical cancer treated with cadonilimab, looking at results, side effects and cost.
Plain-language title generated from the registry record
Registry title: Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Key facts
- Where
- Fuzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with cervical cancer that has persisted, come back or spread, and who are treated with cadonilimab.
- Age
- 18 to 80 years
- Sex
- Women only
- Disease stage
- Persistent, recurrent or metastatic cervical cancer. Squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma. At least one lesion that can be measured on MRI or CT. ECOG score 0-1.
- Earlier treatment
- No earlier treatment with immune checkpoint inhibitors.
Main reasons for not taking part
- Other types of cervical cancer, such as small cell carcinoma, clear cell carcinoma or sarcoma
- Other primary cancers at the same time
- Earlier treatment with immune checkpoint inhibitors
- Reasons the drug cannot be used, such as liver or kidney problems
- The researcher decides the person cannot take part
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06140589, who can take part
Where in China
- No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian ProvinceFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Cancer Hospital
- Trial code
- NCT06140589
- Record updated
- 19 September 2024
- Original description
Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.Read full original descriptionShow less
Study on the Efficacy, Safety and Cost-effectiveness of Cadonilimab in the Treatment of Cervical Cancer
Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.
Inclusion: •Persistent, recurrent or metastatic cervical cancer; The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma; No combination with other multiple primary cancers; MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion; ECOG score 0-1 points; Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms.
Exclusion: Patients with other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc; Previous treatment with immune checkpoint inhibitors; There are drug contraindications, such as liver function Insufficiency, renal insufficiency, etc; The patient withdraws the informed consent; The researcher determines that the patient is not suitable to participate in this clinical study.